Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083174 · ClinicalTrials.gov registry record · Phase 3
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,560
- Enrollment target
NCT00083174: Completed Phase 3 study, sponsored by NCIC Clinical Trials Group.
NCT00083174 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 4,560 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (491% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083174, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,560 participants
- Enrollment target
Study Summary
RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen. PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to complete 5 years of exemestane.
Primary Outcome
Percentage of serious adverse events for women who choose to receive 5 years of exemestane as preventative therapy.
Interventions
- DRUG exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,560 participants |
| Start Date | 2004-12-03 |
| Est. Completion | 2018-01-22 |
| Phase | Phase 3 |
What the finished NCT00083174 record still lists
NCT00083174 is an interventional study that assigns participants to a tested intervention. Its 4,560 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (491% higher).
The record links to 0 conditions, and to 1 intervention - of which exemestane is the first listed.
NCT00083174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00083174 about?
NCT00083174 is a clinical study titled "Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer". RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen. PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to c...
What is the current status of trial NCT00083174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,560 participants. The study started on 2004-12-03. Estimated completion is 2018-01-22.
What interventions are being tested in trial NCT00083174?
The interventions under investigation include: exemestane (DRUG).
Who is sponsoring clinical trial NCT00083174?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00083174's enrollment target sits among peer trials
4,560 54th of 2000 higher than 1,947 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05768217 · 4,600 participants · NA
Community Resiliency Collective Efficacy Intervention
- NCT06702878 · 4,514 participants · Phase 3
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI